Atriance launched for lymph cancer

GSK has launched Atriance (nelarabine) for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded, or has relapsed, following treatment with at least two chemotherapy regimens.

Further information: GSK 0800 221441

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A woman leans on a desk holding her stomach in pain.

Draft NICE approval for new fibroid treatment

Around 4500 women in England and Wales will be eligible...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...